Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Critical Pharmaceuticals has revealed positive results for its proprietary CriticalSorb nasal drug delivery technology from its pre-clinical study and is advancing to a phase I clinical trial.
Subscribe to our email newsletter
The company is developing the technology with the support received from a Wellcome Trust Translation Award and the technology will lead to the development of a nasal formulation of human growth hormone (CP024).
The toxicology study had been designed to evaluate the effects of repeated intranasal administration over a period of six months and a chronic study had been conducted over a period of two weeks. Both the studies showed no adverse effects.
Critical Pharmaceuticals CEO Lisbeth Illum said the company has already demonstrated that CriticalSorb can achieve bioavailabilities for drugs that are difficult to deliver and these latest results confirm that the technology is well tolerated and doesn’t damage the nasal mucosa.